Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/1681
Title: | Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic. | Authors: | Labaki, C. Schmidt, A. L. Bakouny, Z. Labban, M. El Zarif, T. Chang, S. L. McGregor, B. A. Kibel, A. S. Rebbeck, T. Trinh, Q. D. Choueiri, T. K. |
Issue Date: | 2022 | Source: | DOI: 10.1200/JCO.2022.40.6_suppl.281 Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 281-281. Published online February 16, 2022. | Journal: | Journal of Clinical Oncology | Abstract: | Background: The COVID-19 pandemic has been associated with a significant disruption in healthcare services including cancer screening and diagnosis. Delays in cancer screening and treatment may lead to increased mortality. We aimed to analyze changes in screening, diagnosis and surgical treatment of common GU malignancies in relation to the COVID-19 pandemic. Methods: We evaluated screening, novel diagnoses, and surgical management modalities of prostate cancer (PCa), urothelial carcinoma (UC) and renal cell carcinoma (RCC) within Massachusetts General Brigham, the largest healthcare system in the Northeastern United States, over four 3-month time periods during the pandemic (March 2020- March 2021). The percentage change in screening, diagnoses and management modalities during pandemic periods as compared to the immediate pre-pandemic period (December 2019-March 2020) was calculated as (Nperiod – Ncontrol)/Ncontrol. The difference in “predicted” versus “observed” diagnoses in each pandemic period was compared to the average of the four preceding 3-month periods (March 2019-March 2020) to account for seasonal variation. Results: The first pandemic peak (March-June 2020) was associated with a significant decline across screening, diagnosis and treatment, ranging from -15.7 to -64.8%, followed by a progressive recovery, ranging from -5.9 to +25.1% in the latest period (December 2020-March 2021) (Table). Although 725 diagnoses were “missed“ between March and June 2020 as compared to the previous 12 months, 971 diagnoses were “recovered” between June 2020 and March 2021. Conclusions: A substantial disruption in the screening, diagnosis and treatment of GU malignancies was observed early in the pandemic, followed by a progressive rebound and recovery. The highest declines were observed for PSA screening, and the lowest for cystectomy procedures, reflecting triaging of care based on severity during the pandemic. | Description: | Cairns & Hinterland Hospital and Health Service (CHHHS) affiliated author: Andrew Lachlan Schmidt | DOI: | 10.1200/JCO.2022.40.6_suppl.281 | Type: | Article |
Appears in Sites: | Cairns & Hinterland HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.